Research and Development
-
Embla Medical hf: Q4 and Full Year 2025 Interim Report
Embla Medical announced its Q4 and full-year 2025 financial results, highlighting strong revenue growth driven by international product adoption. The company focused on R&D for next-generation AI-powered devices and expanded its intellectual property portfolio. Investments were made to optimize the supply chain and manufacturing for resilience. Embla Medical is optimistic about future growth, with a robust pipeline and strategic partnerships planned to advance healthcare technology.
-
Exelixis Appoints Dana T. Aftab as EVP of Research and Development
Exelixis, Inc. announced the promotion of Dana T. Aftab, Ph.D., to Executive Vice President, Research and Development. Aftab, with 25 years at Exelixis, will lead drug discovery, translational research, product development, and medical affairs. She played a critical role in developing CABOMETYX® (cabozantinib). The company aims to maximize its portfolio, including zanzalintinib. Amy Peterson, M.D., previously Executive Vice President, Product Development & Medical Affairs, has left Exelixis. Exelixis is focused on creating next-generation oncology medicines.
